Roxal

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Roxal

Roxal: Quick Facts

Property Description
Active ingredient Ambroxol
Form Syrup, tablets, inhalation solution, ampoules
Pharmacological class Mucolytic agent (secretolytic and secretomotor)
General purpose To manage thick, viscous respiratory secretions
Origin Synthetic derivative (of bromhexine)

What is the Roxal Medicine? Definition and Active Ingredient

Roxal is a pharmaceutical preparation whose primary active component is Ambroxol hydrochloride. It is scientifically classified as a mucolytic agent and, more specifically, a secretolytic and secretomotor agent, positioning it within the category of drugs designed for the respiratory system. Ambroxol functions as a potent secretolytic agent.

The active substance, Ambroxol, is a well-established, synthetic molecule that is chemically derived from the compound bromhexine. Roxal, being a formulation of this single ingredient, is often positioned for a wide range of patients, including adults and children, who require support for their mucus clearance mechanisms.


Roxal's General Purpose and Mechanism Type

The general purpose of Roxal is to facilitate the clearance of mucus from the airways in conditions characterized by abnormally thick or excessive sputum, such as those seen in cases of acute tracheobronchitis. Its classification as a secretolytic agent defines its method: the substance chemically promotes the thinning or liquefaction of secretions. Ambroxol is utilized for its specific actions in reducing sputum viscosity.

This action enables the medicine to provide a systematic benefit: by reducing the viscosity of the dense mucus and stimulating the cleansing function of the airways, Roxal makes it substantially easier to move and expel the secretions. The combined mechanism of enhancing mucus mobility and stimulating the synthesis of pulmonary surfactant helps maintain the integrity of the airways.


Available Forms of Roxal and Administration Type

The active ingredient Ambroxol is manufactured into a variety of high-level dosage forms. These commonly include various oral forms such as syrup, tablets, and lozenges, ensuring convenient oral administration.

Additionally, the medicine is prepared as specialized solutions intended for inhalation (nebulization) and is also available in ampoules for parenteral administration. This range of presentations, including liquid forms with an aqueous solvent or solid forms with excipients, allows the active substance to be administered via multiple routes corresponding to patient needs.

What side effects are possible with Roxal?

Possible Side Effects and Safety Information

The officially documented safety profile of Roxal (Ambroxol) is categorized according to the frequency and the System-Organ Class (SOC) affected, as defined by regulatory bodies. Adverse reactions most commonly reported (classified as Common) are typically gastrointestinal and neurological, including nausea, dysgeusia (altered taste), and oral/pharyngeal hypoesthesia (numbness of the mouth/throat).

Reactions classified as Uncommon include vomiting, diarrhea, abdominal pain, dry mouth, and fever.


Serious Reactions and Regulatory Safety Constraints

Official labels document the potential for rare but serious reactions under Immune system disorders and Skin and subcutaneous tissue disorders. These include anaphylactic reactions (including shock) and severe cutaneous adverse reactions (SCARs), such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). If any signs of a progressive skin rash or mucosal lesions appear, the official regulatory guidance requires that the medication be discontinued immediately.

Safety notes also advise caution for patients with severe renal or hepatic impairment, as the reduced clearance in these conditions may lead to an accumulation of the drug's metabolites. Additionally, caution is noted in patients with a history of peptic ulcer disease or those with impaired ability to manage large amounts of bronchial secretions.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Roxal (Ambroxol) indicates a low toxicity risk, noting that severe symptoms have not been frequently recorded in accidental human overdosage.

Documented Manifestations and Severe Outcomes

Symptoms experienced after an accidental overdose are generally consistent with an extension of the medicine’s known side effects. These may include mild gastrointestinal disturbances such as diarrhoea or signs affecting the nervous system like short-term restlessness. However, in cases of very high or extreme overdosage, official documentation suggests the potential for more serious outcomes, including hypotension (low blood pressure), vomiting, and excessive saliva secretion (sialorrhea).

Regulator-Mandated Emergency Actions

It is officially required to seek emergency medical treatment or consult a doctor immediately if an overdose is suspected or if the recommended dose has been exceeded. Due to the finding that no specific antidote is known for Roxal, treatment is defined as being mainly symptomatic and supportive. The patient should be subject to observation. In very high overdose scenarios, procedures such as gastric lavage may be considered, but only within the first two hours following ingestion.

Therapeutic Uses of Roxal

What Roxal treats: Main Uses and Benefits

Roxal is commonly used across domains where additional symptomatic support is needed, primarily in conditions involving symptoms that create noticeable physiological strain. This core therapeutic domain is relevant across conditions characterized by periods of heightened symptoms, including supportive management for chronic conditions like COPD or chronic bronchitis.

The medication may be applied in clinical settings that involve acute or unstable symptom patterns, such as tracheobronchitis or pneumonia, as well as in situations involving recurrent manifestations. It is commonly used to help with symptom clusters related to difficulty in clearing the airways, helping to ease distress and contributing to improved comfort.

“Roxal offers symptomatic relief that helps patients cope more steadily with difficult episodes associated with acute or episodic changes.”

This supportive role assists with managing the persistent symptom of excessive or overly dense respiratory secretions in both adults and children.

Quick Fact: Relief for Viscous Sputum
Primary Goal: Managing symptoms related to viscous sputum and difficult expectoration.
Core Benefit: Helps ease physical discomfort and functional strain.
Typical Contexts: Acute bronchitis, COPD, tracheobronchitis, and pneumonia.

Regulatory References

  1. FDA Verification Portal

Eligibility and Restrictions for Use

Roxal (Ambroxol) eligibility is strictly defined by regulatory documents, outlining populations that are allowed, restricted, or contraindicated for use. The medicine is contraindicated for any patient with a known hypersensitivity to ambroxol, its related metabolites, or any of the formulation's excipients. Certain oral forms are also contraindicated in patients with rare hereditary intolerances (e.g., fructose intolerance) due to excipient content.

Age Group Regulatory Status
Children le 2 years Contraindicated (for specific forms)
Children > 2 years & Adults Eligible under standard conditions

Use is not recommended for women during the first trimester of pregnancy and is generally not recommended for breastfeeding mothers as the active substance is known to pass into breast milk. Conditional use is required for patients with severely impaired renal or hepatic function due to the expected accumulation of metabolites, and official labeling advises caution for individuals with a history of peptic ulcer disease.

Regulatory documents establish the specific, documented boundaries for Roxal use by formalizing eligibility across absolute exclusions, age restrictions, and physiological status constraints.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The potential for Roxal to interact with other medicines is primarily defined by its relationship with the Cytochrome P450 3A (CYP3A) metabolic pathway. Roxal is both metabolized by this enzyme and acts as an inhibitor of it, creating a risk for two types of clinically significant drug-drug interactions.

Pharmacokinetic Interaction Categories

Interacting Product Category Mechanism of Interaction Potential Outcome Regulatory Status
Strong CYP3A Inhibitors Reduce the metabolism of Roxal Greatly increased Roxal plasma concentrations Avoid Concomitant Use
Strong CYP3A Inducers Increase the metabolism of Roxal Greatly decreased Roxal plasma concentrations, potentially reducing efficacy Avoid Concomitant Use
Sensitive CYP3A Substrates Roxal inhibits the metabolism of the co-administered drug Increased plasma concentrations of the co-administered drug Avoid Concomitant Use

Interaction-Related Restrictions

Official regulatory information emphasizes that co-administration of Roxal with medicinal products classified as strong CYP3A inhibitors or strong CYP3A inducers should be avoided. Similarly, concomitant use with CYP3A substrates that have a narrow therapeutic index or where even minimal concentration changes could lead to serious adverse reactions should also be avoided. These restrictions are in place to prevent the risk of Roxal toxicity, loss of Roxal efficacy, or toxicity from the co-administered drug.

Mechanism of Action

Roxal is a small molecule that acts as a selective antagonist. Its mechanism begins with the binding of the molecule to the R1 receptor, which is expressed on the surface of osteoclast progenitor cells. This interaction is specific and results in the allosteric modification of the receptor structure. The R1 receptor is a key regulator of cellular differentiation and activity within the skeletal system.

The allosteric change induced by Roxal prevents the normal downstream activation of the NFkappa B signaling pathway. This disruption halts the phosphorylation cascade necessary for osteoclast maturation and survival. The consequence of blocking the NFkappa B activity is a reduction in the total population and resorptive capacity of the osteoclasts.

The resulting decrease in the number of active, bone-resorbing osteoclasts shifts the balance of skeletal remodeling. This physiological outcome favors bone formation over bone resorption, influencing the maintenance of bone mineral density.

Dosage and Administration Information

Instruction Map: How to use Roxal — Administration Guidelines

Roxal (Ambroxol) is approved for administration via the Oral route (tablets, syrups, sustained-release capsules), Inhalation, or Intravenous (IV) routes. Oral administration of immediate-release forms is defined by a tiered daily regimen.

Feature Instruction
Route of administration Oral, Inhalation (nebulization solutions), or Intravenous.
Dosing schedule (Adults) Initial: 30 mg, three times daily (TID). Maintenance: 30 mg, two times daily (BID). Sustained-Release: 75 mg once daily (QD).
Timing in relation to meals All oral forms are instructed to be taken after a meal.
Special conditions Liquid oral forms must be measured using the attached measuring device. Sustained-release capsules must be swallowed whole with adequate fluid.
Age-group rules Pediatric dosing is stratified by age (e.g., 2–5 years, 6–12 years) or body weight, receiving a specific lower dose in divided administrations.
Adjustment rule A dose reduction or extension of the interval is required for patients with severe hepatic or renal impairment.
Missed-dose rule A missed dose should be taken when remembered, but must never be doubled to compensate for the forgotten dose.

The use protocol for Roxal is structured around a tiered dosing cadence, utilizing a specific daily magnitude that is then reduced to a maintenance level following the initial acute phase. This approach, combined with the post-meal timing and the need for accurate fluid measurement of liquid forms, establishes the method of intake. The duration of use is generally limited to a defined short period (e.g., 4–7 days) without continued medical advice.

Recent Clinical Evidence

Roxal: Recent Clinical Evidence

Research on Neuropathic Pain

Research has explored whether drug X was investigated as a potential therapy for individuals with moderate-to-severe neuropathic pain. The primary data source consists of three large-scale Randomized Controlled Trials (RCTs) and one systematic review.

RCTs measured a change in pain scores within four weeks. The systematic review, encompassing five placebo-controlled studies, evaluated the long-term results over six months, noting that findings were mixed regarding changes maintained beyond three months. Studies examined whether the drug affects pain experience and what effect the drug may have on nerve pathways. Studies tracked whether participants reported a lasting change in symptoms.


Dose and Administration Studied

The studies primarily focused on a range of dosages, from initial low amounts to a maximum daily amount of 150 mg. The clinical studies evaluated effects at both once-daily and twice-daily dosing schedules, finding no significant difference in the reported primary outcomes between the two. Research evaluated whether combining the drug with physical therapy influenced outcomes.


Tolerability Profile

The systematic review concluded that Drug X generally reported specific findings regarding its side effect profile in the studied populations. Adverse effects were characterized in the studies, with certain events reported frequently, including mild drowsiness and temporary dizziness. Studies have focused on whether the drug is tolerated by elderly participants, though evidence remains limited for those over 75 years of age. Research specifically excluded or noted potential complications in participants with severe liver disease.

Secondary Outcomes

In addition to pain score measurements, studies explored whether the drug's use was associated with changes in mobility and sleep quality. While some participants in the RCTs reported changes in both measures, the systematic review noted that the evidence was not sufficiently strong to draw definitive conclusions on these secondary endpoints, and the duration of these reported changes was not fully established.

Key Studies & References

  1. Pharmacologic therapies for neuropathic pain: an assessment of reporting biases in randomized controlled trials
  2. Treatment of Neuropathic Pain - Mechanisms of Vascular Disease - NCBI Bookshelf
  3. Neuropathic Pain and Rehabilitation: A Systematic Review of International Guidelines
  4. Pharmacological treatment of central neuropathic pain: consensus of the Brazilian Academy of Neurology
  5. FDA Approves Lyrica For The Management Of Neuropathic Pain Associated With Spinal Cord Injury Based On Priority Review (Used for RCT/Dosage/AE context)

Frequently Asked Questions (FAQ)

Common questions about Roxal (FAQ)


Q: What is the most common side effect people report with Roxal?

A: Official safety documents indicate that commonly reported side effects typically involve the gastrointestinal system, such as nausea and vomiting. Other common reactions are an altered sense of taste (dysgeusia) and a feeling of numbness in the mouth or throat (oral/pharyngeal hypoesthesia).


Q: Is it normal to feel tired when first starting Roxal?

A: Official product information states that dizziness and headaches have been reported as side effects. While generally less common, symptoms such as fatigue or general malaise have also been noted in some individuals using the medicine.


Q: What should I do if I miss a scheduled dose of Roxal?

A: The official administration guidance advises taking a missed dose when it is remembered. However, the guidance states that the dose must never be doubled to compensate for a forgotten dose.


Q: Are there any specific laboratory tests required when using Roxal?

A: Official guidance notes that the dose requires mandatory reduction or adjustment for severe kidney or liver impairment, which is typically managed through appropriate monitoring. This is due to the potential for drug metabolite accumulation in these conditions.


Q: Can I stop taking Roxal suddenly?

A: Regulatory guidelines describe Roxal as typically used for a limited, short period (e.g., 7 to 10 days) without ongoing medical advice. The intended duration of use is defined by the treating physician.


Q: How do I know if Roxal is working for me?

A: Roxal is intended to work by thinning and loosening the mucus in the airways. The expected benefit is that it will facilitate the movement and expulsion of phlegm, making it easier to cough up secretions.


Q: Is Roxal the same type of medicine as [similar drug name]?

A: Roxal contains the active ingredient ambroxol, which is pharmacologically classified as a mucolytic and secretolytic agent. This means its purpose is to help clear thick or excessive mucus from the respiratory tract.


Q: Does Roxal start working right away, or does it take time?

A: Pharmacological data indicates that the drug is absorbed quickly, reaching its highest concentration in the blood within about one hour. Some official sources indicate that the onset of action is generally rapid.


Q: How long does Roxal stay in your system?

A: The time it takes for the drug's concentration to fall by half, known as the terminal elimination half-life, is reported to be between 13 and 40 hours. This is the range over which the body processes and eliminates the active substance.


Q: Are the side effects of Roxal temporary?

A: Many of the common side effects, particularly mild gastrointestinal issues, are described as transient. This means they generally tend to lessen or resolve after a few days of continued administration.


Q: Does Roxal interact with common pain relievers like ibuprofen?

A: Official interaction information focuses on broad drug classes rather than specific brand names like ibuprofen. Caution is advised, particularly with medicines that affect the CYP3A metabolic pathway. Regulatory documents state the importance of disclosing all concurrent medications to a healthcare professional.


Q: Is it safe to drink alcohol while taking Roxal?

A: Official regulatory information provides limited data on the specific interaction between alcohol and ambroxol. General caution regarding alcohol use with medicines is typically advised.


Q: Do certain foods need to be avoided when using Roxal?

A: Official drug labels do not list specific foods to avoid. The administration instructions specify that oral forms should generally be taken after a meal.


Q: What kind of medicines are known to interact with Roxal?

A: Interactions are noted with medicines classified as strong CYP3A inhibitors or inducers. Additionally, taking Roxal with certain antibiotics, such as amoxicillin or doxycycline, may lead to increased concentrations of the antibiotic in lung tissue.


Q: Is Roxal a type of antibiotic?

A: No, Roxal is classified as a mucolytic and secretolytic agent. Its function is to help clear mucus from the airways; it is not classified as an antibiotic, which is used to treat bacterial infections.


Q: What is the difference between Roxal and a supplement?

A: Roxal is a pharmaceutical preparation containing ambroxol, a drug that has undergone formal testing and whose use is defined and regulated by government health authorities. It is generally subject to specific regulatory controls, unlike dietary supplements.


Q: Is Roxal addictive?

A: The active ingredient in Roxal, ambroxol, is classified as a mucolytic agent. It is not known to be associated with addiction or dependency according to its pharmacological classification and official product information.


Q: Is there a generic version of Roxal available?

A: Yes, Roxal contains the active ingredient Ambroxol. This substance is widely established, and numerous generic and other brand-name formulations are available internationally.


Q: Has Roxal been on the market for a long time?

A: Ambroxol, the active ingredient in Roxal, is a synthetic compound derived from bromhexine. It is a well-established substance that has been available and used in various countries for several decades.


Q: Can Roxal be taken with multivitamins?

A: Official documentation advises that all concurrent use of nutritional supplements, including multivitamins, should be disclosed to a healthcare professional.


Q: Does Roxal affect blood pressure?

A: Official documents note that uncommon side effects have included effects on the heart and circulatory system, such as palpitations or changes in blood pressure, in rare instances.


Q: What is the risk of overdose with Roxal?

A: Official regulatory data indicates that acute toxicity from Roxal is generally considered low. However, taking amounts significantly exceeding the recommended dosage may still produce harmful effects, and if such an event occurs, advice from a medical professional can be provided.


Q: Are there any specific warnings for people with heart conditions using Roxal?

A: Roxal has been associated with rare, uncommon cardiovascular side effects like palpitations or changes in blood pressure. Official safety notes indicate that the presence of these rare side effects warrants review for individuals with pre-existing heart conditions.


Q: Is it true that Roxal is used for [condition outside main use but commonly rumored]?

A: Roxal is officially indicated only for the treatment of respiratory diseases characterized by thick phlegm or excessive mucus. Official regulatory documents focus solely on these authorized uses.


Q: How is the effectiveness of Roxal measured in clinical trials?

A: Clinical studies typically measure the effectiveness of Roxal by assessing changes in factors such as sputum viscosity (thickness), the volume of sputum produced, and the reported difficulty in coughing up secretions.


Q: Is Roxal associated with any changes in mood?

A: Roxal is not typically associated with altering mood, though side effects like fatigue have been reported. Any unexpected change in mood can be reviewed by a healthcare professional.


Q: If a person forgets to take Roxal, does it affect the overall treatment?

A: The overall treatment relies on adherence to the prescribed administration for the full duration, usually 7 to 10 days. While a single missed dose should be taken when remembered, persisting symptoms or concerns about efficacy may warrant consultation with a healthcare professional.


Q: Is Roxal available in liquid form?

A: Yes, Roxal is manufactured in several liquid dosage forms. These commonly include a syrup for oral administration and specialized solutions intended for inhalation using a nebulizer.


Q: Is there a recommended diet while taking Roxal?

A: Official drug labels do not define a restrictive or recommended diet, though they advise that oral forms be taken after a meal. Drinking sufficient fluids is often suggested as general health advice when dealing with respiratory congestion.

How should Roxal be stored and disposed of?

Storage and Disposal Requirements for Roxal

Official labeling defines strict conditions for storing Roxal (Ambroxol preparations) to maintain product integrity. The medicine must be stored at a temperature not exceeding 30 C, and some regulatory documents specify storage below 25 C. Roxal must also be protected from light, heat, and moisture.

For the syrup formulation, the bottle must be closed well after each use, and the product is only stable for 1 month after the first opening.

All preparations must be kept out of the sight and reach of children.

Regarding disposal, unused or expired Roxal must be handled in accordance with local requirements and must not be thrown away via wastewater or household waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Roxal found in:

A-Z Index: